References

  1. Cyanokit (single 5-g vial) [package insert]. Columbia, MD: Meridian Medical Technologies, Inc.; 2011.
  2. Eckstein M, Maniscalco PM. Focus on smoke inhalation–the most common cause of acute cyanide poisoning. Prehosp Disaster Med. 2006;21(2):s49-s55.
  3. Benner JP, Lawrence D, Brady W. Smoke signals. Recognition and treatment of combustion-induced cyanide toxicity. JEMS. 2009;34(10):56-63.
  4. Borron SW, Baud FJ, Barriot P, Imbert M, Bismuth C. Prospective study of hydroxocobalamin for acute cyanide poisoning in smoke inhalation. Ann Emerg Med. 2007;49(6):794-801.
  5. Borron SW, Stonerook M, Reid F. Efficacy of hydroxocobalamin for the treatment of acute cyanide poisoning in adult beagle dogs. Clin Toxicol (Phila). 2006;44(suppl 1):5-15.
  6. Lawson-Smith P, Jansen EC, Hyldegaard O. Cyanide intoxication as part of smoke inhalation–a review on diagnosis and treatment from the emergency perspective. Scand J Trauma Resusc Emerg Med. 2011;19:1-5.
  7. Baud FJ, Borron SW, Mégarbane B, et al. Value of lactic acidosis in the assessment of the severity of acute cyanide poisoning. Crit Care Med. 2002;30(9):2044-2050.
  8. Torres EC, Bustamante RS, Granizo EG, et al. Hydroxocobalamin and lactate concentration in patients suspected of having cyanuric acid poisoning related to smoke inhalation syndrome. Emergencias. 2010;22:9-14.
  9. Schnepp R. Where there's fire—there's smoke! In: Smoke: Cyanide and Carbon Monoxide: The Toxic Twins of Smoke Inhalation. Indianapolis, IN: Cyanide Poisoning Treatment Coalition; 2009:3-8.
  10. Lee-Chiong TL Jr. Smoke inhalation injury: when to suspect and how to treat. Postgrad Med. 1999;105(2):55-62.
  11. Borron SW, Baud FJ, Megarbane B, Bismuth C. Hydroxocobalamin for severe acute cyanide poisoning by ingestion or inhalation. Am J Emerg Med. 2007;25(5):551-558.
  12. Fortin JL, Giocanti JP, Ruttimann M, Kowalski JJ. Prehospital administration of hydroxocobalamin for smoke inhalation-associated cyanide poisoning: 8 years of experience in the Paris Fire Brigade. Clin Toxicol (Phila). 2006;44(suppl 1):37-44.
  13. Uhl W, Nolting A, Golor G, Rost KL, Kovar A. Safety of hydroxocobalamin in healthy volunteers in a randomized, placebo-controlled study. Clin Toxicol (Phila). 2006;44(suppl 1):17-28.
  14. Hall AH, Saiers J, Baud F. Which cyanide antidote? Crit Rev Toxicol. 2009;39(7):541-552.
  15. Cyanokit (two 2.5-g vials) [package insert]. Columbia, MD: Meridian Medical Technologies, Inc.; 2011.
  16. Guidotti T. Acute cyanide poisoning in prehospital care: new challenges, new tools for intervention. Prehosp Disaster Med. 2005;21(2):s40-s48.
  17. Alarie Y. Toxicity of fire smoke. Crit Rev Toxicol. 2002;32(4):259-289.
  18. Agency for Toxic Substances and Disease Registry. Cyanide toxicity. Am Fam Physician. 1993;48(1):107-114.
  19. Walsh DW, Eckstein M. Hydrogen cyanide in fire smoke: an underappreciated threat. Emerg Med Serv. 2004;33(10):160-163.
  20. Hertzberg T, Blomqvist P, Dalene M, Skarping G. Particles and Isocyanates From Fires. Borås, Sweden: SP Swedish National Testing and Research Institute; 2005:1-51.
  21. O'Brien DJ, Augustine J, Walsh DW. Cyanide exposure, smoke inhalation, and pre-hospital treatment: recognizing the signs and symptoms and available treatment options. In: Smoke: Cyanide and Carbon Monoxide: The Toxic Twins of Smoke Inhalation. Cyanide Poisoning Treatment Coalition: Indianapolis, IN: 2009:20-24.
  22. Maniscalco PM. From smoke inhalation to chemical attacks: acute cyanide poisoning in the prehospital setting. Prehosp Disaster Med. 2006;21(2):s38-s39.
  23. Alcorta R. Smoke inhalation & acute cyanide poisoning. In: Losavio K, ed. Smoke Inhalation & Hydrogen Cyanide Poisoning. San Diego, CA: JEMS Communications; 2004:6-17.
  24. Division of Toxicology, Agency for Toxic Substances and Disease Registry. Toxicological profile for cyanide. http://www.atsdr.cdc.gov/toxprofiles/tp.asp?id=72&tid=19. Updated October 19, 2007. Accessed October 25, 2011.
  25. Research Triangle Institute International. Cyanide: understanding the risk, enhancing preparedness. Clin Toxicol (Phila). 2006;44
    (suppl 1):S47-S63.
  26. Keim ME. Terrorism involving cyanide: the prospect of improving preparedness in the prehospital setting. Prehosp Disaster Med. 2006;21(2):s56-s60.
  27. Dept of Homeland Security. Authorized equipment list. https://www.rkb.us/mel.aspx?subtypeid=549. Accessed October 25, 2011.
  28. FDA Press Release. FDA approves drug to treat cyanide poisoning. US Food and Drug Administration. December 15, 2006.
  29. EMEA. European Public Assessment Report. Cyanokit, 2007.
  30. Borron SW. Recognition and treatment of acute cyanide poisoning. J Emerg Nurs. 2006;32(4 suppl):s12-s18.


Indication
CYANOKIT® (hydroxocobalamin for injection) 5 g for intravenous infusion is indicated for the treatment of known or suspected cyanide poisoning. If clinical suspicion of cyanide poisoning is high, CYANOKIT® should be administered without delay.

Important Safety Information
Cyanide poisoning may result from inhalation, ingestion, or dermal exposure. Prior to administration of CYANOKIT®, smoke-inhalation victims should be assessed for: exposure to fire or smoke in an enclosed area; presence of soot around the mouth, nose, or oropharynx, and altered mental status. In addition to CYANOKIT®, treatment of cyanide poisoning must include immediate attention to airway patency, adequacy of oxygenation and hydration, cardiovascular support, and management of any seizure activity.

Use caution in the management of patients with known anaphylactic reactions to hydroxocobalamin or cyanocobalamin. Allergic reactions may include: anaphylaxis, chest tightness, edema, urticaria, pruritus, dyspnea, rash, and angioneurotic edema. Substantial increases in blood pressure may occur following CYANOKIT® therapy. Usage may interfere with some clinical laboratory evaluations. Also, because of its deep red color, hydroxocobalamin may cause hemodialysis machines to shut down due to an erroneous detection of a "blood leak." This should be considered before hemodialysis is initiated in patients treated with hydroxocobalamin. Due to potential photosensitivity, patients should avoid direct sun until erythema resolves.

CYANOKIT® is Pregnancy Category C and should be used during pregnancy only if the potential benefit justifies the potential risk. Safety and effectiveness of CYANOKIT® have not been established in pediatric patients. The most common adverse reactions (>5%) are transient and include chromaturia, erythema, rash (predominantly acneiform), increased blood pressure, nausea, headache, decreased lymphocyte percentage, and injection site reactions.

Please see single 5-g vial full Prescribing Information. Please see two 2.5-g vial full Prescribing Information.

DISCLAIMER
This Web site is intended only for First Responders and Healthcare Professionals and is subject to all applicable US laws. The product information provided in this site is intended only for residents of the United States. The products discussed herein may have different product labeling in different countries.